Osmind presented comparative efficacy data for intravenous ketamine versus nasal esketamine at ASCP, offering clinical insights relevant to treatment-resistant depression management.
A case report demonstrates that combining diazepam and aripiprazole effectively treats catatonic stupor in a high-risk patient with pulmonary embolism who could not undergo electroconvulsive therapy.
Nervigen's roluperidone, a potential treatment for schizophrenia negative symptoms, is awaiting pivotal clinical data expected in 2027.
Positive Phase 2 topline data for elunetirom, a CNS-targeted thyroid receptor agonist, demonstrates rapid and significant efficacy as an adjunctive treatment for bipolar depression with a favorable safety profile.
UCSF has selected Filament Health's PEX010, a standardized natural psilocybin candidate, for a study investigating preclinical Alzheimer's disease markers.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from May 29 – Jun 05)
- Consider elunetirom as a potential adjunctive option for bipolar depression given its Phase 2 data showing rapid, robust, and durable efficacy with a favorable safety profile.
- Re-evaluate the necessity of long-term antidepressant monotherapy beyond 12 months for relapse prevention, as recent evidence suggests benefits may be overstated and regular reviews are warranted.
- Exercise extreme caution when prescribing D2 receptor antagonist antiemetics like metoclopramide to patients with conditions involving blood-brain barrier compromise due to the risk of precipitating catatonia.
- Utilize N-acetylcysteine as a low-risk adjunctive strategy for patients with comorbid bipolar disorder and alcohol use disorder, supported by its ability to reduce dorsal anterior cingulate cortex glutamate levels and heavy drinking days.
- Recognize that BXCL501 (intranasal midazolam) is an effective home-based intervention for acute agitation in patients with bipolar disorder and schizophrenia.
- Anticipate that higher baseline OCD severity predicts better long-term outcomes for deep brain stimulation, while concurrent use of antipsychotics and antidepressants may predict poorer results.
- Note that spectral EEG-guided personalized TMS shows promise in reducing social anxiety symptoms and normalizing EEG patterns, warranting consideration as an adjunctive treatment option.
- Be aware that Luvesilocin, a novel psychedelic prodrug targeting the 5-HT2A receptor, has entered Phase 2 trials for postpartum depression, offering a potential episodic dosing model distinct from daily psychotropics.
Journal Article 1
A new study challenges the long-term efficacy of antidepressants for relapse prevention beyond 12 months, suggesting benefits may be overstated.
Clinical Pearl 2
This case report highlights the risk of catatonia precipitated by D2 receptor antagonist antiemetics (metoclopramide and domperidone) in patients with multiple sclerosis, emphasizing the need for caution when prescribing these agents to individuals with blood-brain barrier compromise.
A randomized crossover trial found that N-acetylcysteine, but not gabapentin, significantly reduced dorsal anterior cingulate cortex glutamate levels and heavy drinking days in patients with comorbid bipolar disorder and alcohol use disorder, supporting further mechanistic trials of glutamatergic modulation.
Drug Development 2
Autobahn Therapeutics reported positive Phase 2 topline data for elunetirom in bipolar depression, showing rapid, robust, and durable antidepressant effects.
A clinical trial is evaluating the dopamine D2 and D3 receptor occupancy of SIPI6398, a novel investigational agent for schizophrenia.
Pharmacogenomics 1
Research suggests a saliva-based biomarker may predict individual response to ADHD medications, offering a potential tool for precision prescribing.
Podcast Summary 1
This podcast episode reviews the neurobiology and therapeutic potential of neuromodulation (TMS/SAINT) and psychedelic-assisted therapies (psilocybin, MDMA, ibogaine, ayahuasca) for depression and PTSD, though it lacks specific clinical trial data or prescribing guidelines.
Diagnosis & Treatment 4
A completed clinical trial comparing the Reacor adaptive biofeedback system, escitalopram, and their combination for the treatment of anxiety disorders.
A meta-analysis identifies higher baseline OCD severity as a predictor of long-term response to deep brain stimulation, while concurrent antipsychotic and antidepressant use predicts poorer outcomes.
A review published in the Australian Journal of General Practice suggests limited benefit and increased health risks for antidepressant use beyond 12 months, recommending regular treatment reviews.
Digital Health 1
A case report suggests spectral EEG-guided personalized TMS may reduce social anxiety symptoms and normalize EEG patterns, warranting further investigation as an adjunctive treatment.
Neuroscience 1
This systematic review of fMRI studies identifies specific neural circuit alterations in PMDD, providing a mechanistic basis for the partial non-response to SSRIs and informing the development of novel therapeutic targets.
Policy & Regulation 3
Axsome Therapeutics has settled with the last applicant to delay generic competition for the narcolepsy drug Sunosi until 2040, preserving market exclusivity.
The FDA issued a Complete Response Letter for CTx-1301, a potential new treatment for ADHD, indicating regulatory hurdles for this psychopharmacologic candidate.
Axsome Therapeutics has settled patent litigation for the narcolepsy drug Sunosi (solriamfetol), delaying generic competition until 2040 and securing market exclusivity while the company expands its indications to ADHD and depression.
Mechanism of Action 1
This review synthesizes translational research on oxytocin therapy for schizophrenia negative symptoms, detailing its multi-target neural mechanisms and highlighting the need for precision psychiatry approaches to address clinical heterogeneity.